Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000405

Drug Information
NameMinocycline    
SynonymsCHEMBL259172; NSC 141993; Minociclina [INN-Spanish]; MIY; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; CRL-1605 & Minocycline; CID5281021; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; Minociclina; NSC141993; Minocycline [USAN:BAN:INN]; Minocycline (USAN/INN); CHEBI:529981; Borymycin; 10118-90-8; LMPK07000002; AC1NQXWM; nchembio.559-comp1; Lactoferrin B & Minocycline; CHEBI:50694; MINO; CL 59806; Minocycline Monohydrochloride; Bio-0062; Minocline; Minocyclinum; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,12aalpha))-; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-; NCGC00178854-01; Minocin (Hydrochloride); UNII-FYY3R43WGO; 4708-96-7; Lactoferrin H & Minocycline; Minocyclin; LS-93850; minociclinum; Minocyclinum [INN-Latin]; minocycline; BRN 3077644; C23H27N3O7; Minocin; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; CHEMBL1434; 13614-98-7 (mono-hydrochloride); HSDB 3130; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; D05045; C07225; Vectrin (Hydrochloride); HMS2090D03    
Trade NameMinocin    
CompanyLederle Laboratories    
IndicationBacterial infectionsApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntibacterial Agents    
CAS NumberCAS 10118-90-8
FormularC23H27N3O7    
PubChem Compound IDCID 5281021.    
PubChem Substance IDSID 9434.    
ChEBI50694;    
SuperDrug ATC IDJ01AA08;    
SuperDrug CAS ID010118908;    
Target30S ribosomal subunitBinder[2]
Ref 1Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. To Reference
Ref 2Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543